Dr. Paul Nunzio DeSantis

About the Author Dr. Paul Nunzio DeSantis

Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.

http://propthink.com/gileadreport/

http://www.alphabiopharmaadvisers.com

http://www.linkedin.com/pub/dr-paul-nunzio-de-santis-pharm-d/31/994/b57

Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%25252c-pharm.d

Intercept Pharmaceuticals Inc (ICPT): Reassessing OCA’s Value Proposition and Potential Takeover Valuations

Background Shares in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) climbed as much as +31% on February 12th following a report from Reuters citing anonymous sources …

Gilead Sciences, Inc. (GILD): Options Market Mispricing Risk

The options market appears to be underestimating the risk to Gilead Sciences, Inc. (NASDAQ:GILD)’s share price ahead of an event that could intensify …

Incyte Corporation (INCY): Bullish Option’s Positioning Supports Upside On Gilead Sciences, Inc. (GILD) M&A Thesis

After the market close on September 11th, Gilead Sciences, Inc. (NASDAQ:GILD) announced that it had raised $9.

Kite Pharma Inc: Regulatory, Commercial, and Clinical Viewpoints

Regulatory Viewpoints The market punished Kite Pharma Inc (NASDAQ:KITE)’s shares during the first half of August selling off -30% from the close on …

Gilead Sciences, Inc. (GILD): Growth Still Not Over

As we anticipated, Gilead Sciences, Inc. (NASDAQ:GILD)’s Implied VOL increased ~15-20% on a relative basis from 7/12/15 until today’s close.

Vertex Pharmaceuticals Incorporated’s Short-Term Dominance in Cystic Fibrosis is Questionable Longer Term

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s weekly options are pricing in a move of +/- $10 with Implied VOL currently in the 28th percentile over …

Gilead Sciences, Inc. (GILD): Owning Ahead Of Earnings To Position For Catalysts And Seasonality Outperformance

Herein we discuss several important drivers for Gilead Sciences, Inc. (NASDAQ:GILD) shares going into 2Q15/2016.

Karyopharm Therapeutics Inc: Solid Tumor Opportunity With Significant Upside Potential

Karyopharm Therapeutics Inc (NASDAQ:KPTI) is catalyst rich over the next 18-months and is at onset of a multi-year re-rate higher. We contend that …

Will Gilead Sciences, Inc (GILD) Acquire Vertex Pharmaceuticals Incorporated (VRTX) Despite its Short-Term Dominance In Cystic Fibrosis?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) weekly options are pricing in a move of +/- $10 with Implied VOL currently in the 28th percentile over the …

Clovis Oncology Inc 1Q15 Update: Alpha BioPharm Presents Positive Outlook

Clovis Oncology Inc (NASDAQ:CLVS) management did a great job setting realistic expectations during 1Q15 conference call on both regulatory timelines, and data releases …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts